Abstract: The use of interleukin-2 (IL-2) for the stimulation of an effector immune response against metastatic cancer dates back to the early 1980s. Administration of unmodified IL-2, either alone or together with antigen-specific approaches, has resulted in remarkably long-term survival of some patients suffering from metastatic melanoma. However, such treatment is usually hampered by the appearance of toxic adverse effects, which has motivated the engineering of modified IL-2 formulations showing reduced toxicity while being more potent at stimulating anti-tumor effector immune cells. In this review we summarize and discuss the features and biological relevance of several enhanced IL-2 formulations, compare these to IL-15-based therapeutics, and try to foreshadow their potential in immunological research and immunotherapy. 
Introduction
Interleukin-2 (IL-2) is a small 15.5 kDa four -helical bundle cytokine, which plays crucial roles both during the resting and activated states of the immune system [1] .
The main function of IL-2 during steady-state conditions appears to lie in the development and survival of CD4 + forkhead box p3 (Foxp3) + regulatory T-cells (Tregs), thus governing peripheral immune tolerance [2] . Conversely, during an immune response, IL-2 acts as a 'growth factor' of effector immune cells by supporting the proliferation and expansion of effector and memory T-cells and natural killer (NK) cells, and also enhances effector functions of these cells [1] [2] [3] .
IL-2 can bind to three different IL-2 receptors (IL-2R): IL-2R (CD25) alone, a heterodimer of IL-2R (CD122) and IL-2R (also referred to as common -chain
receptor, c), and a heterotrimer of CD25, CD122 and c, which are called the low-, intermediate-, and high-affinity IL-2R, respectively ( Figure 1A ). CD122 and c are crucial for signaling upon IL-2 binding, whereas CD25 does not appear to signal but increases receptor affinity [3, 4] .
While c expression remains rather stable, CD25 is up-regulated on recently activated T-cells, along with a moderate elevation of CD122, thereby leading to increased sensitivity of these cells to autocrine and paracrine IL-2. On resting immune cells, CD25 is mainly confined to Tregs, which also express the other IL-2R subunits, thus showing high sensitivity to IL-2. Recently antigen-stimulated T-cells express CD25 mirroring their high dependency on IL-2 during the expansion phase [3, 5] . Interestingly, during later stages of an immune response, antigen-experienced (memory) CD8 + T-cells and NK cells express very high levels of CD122 (higher than on Tregs) along with c and are thus able to compete with Tregs for IL-2 [6, 7] .
IL-2 is a secreted primarily by activated CD4 + T-cells, but also CD8 + T-cells, NK and NKT-cells, DCs, and mast cells are able to produce IL-2 following activation [1, 2, 8] .
Owing to its potent T-cell growth-stimulating properties, IL-2 administration has been successfully used since the early 1980s as a cancer immunotherapy [9] [10] [11] .
There, IL-2 proved beneficial in patients with end-stage metastatic melanoma or renal cell carcinoma (Figure 2 ), especially when given as high-dose (HD) IL-2 consisting of 600'000-720'000 international units per kg body weight per infusion, administered every 8 hours for a maximum of 14 doses [9, 11] . However, the widespread use of IL-2 is hampered by dose-dependent adverse effects, such as hypotension, pulmonary edema, liver cell damage and renal failure. Pathophysiologically, these phenomena appear to result from increased vascular permeability leading to vascular leak syndrome (VLS) [12, 13] .
Another complicating factor is that IL-2 has a short half-life of 20-30 minutes in the blood in vivo, as it is rapidly cleared by the renal system upon intravenous (iv)
injection [12, 14, 15] 
IL-2/anti-IL-2 mAb complexes
IL-2-cx are generated by the association of murine or human IL-2 with specific mAbs (Table 1) [6, 18, 20] .
While the process of complexing IL-2 with a specific anti-IL-2 mAb is rather simple, the complete dissociation of IL-2 from the mAb can be avoided by introducing a flexible linker between IL-2 and the mAb [21] .
With the production of humanized or fully human anti-human IL-2 mAbs and the generation of single-molecule IL-2-cx, this technology might soon become available for testing in the clinic.
IL-2 muteins
Other strategies have focused on mutated forms of IL-2 (IL-2 muteins). While some IL-2 muteins were designed to target dimeric IL-2Rs, hence leading to the preferential stimulation of memory CD8 + T-cells and NK cells, other IL-2 muteins favor cells expressing high levels of CD25, such as recently-activated T-cells, but also Tregs, the latter of which was less obvious when these molecules were engineered ( Table   1 ).
The mutein 'IL-2 superkine' was generated by several amino acid substitutions However, compared to IL-2-cx, the anti-tumor efficacy of IL-2 superkine was weaker and could not be significantly improved by repetitive treatment cycles or formulation of an IL-2 superkine-Fc construct with longer in vivo activity (unpublished data). As for toxic adverse effects, IL-2 superkine showed, similar to IL-2-cx, reduced IL-2-related pulmonary edema and liver cell damage.
With the aim of reducing the affinity of IL-2 to CD25, another IL-2 mutein (termed 'no- mutein') was generated by introducing an alanine at positions R38, F42, Y45, and E62, resulting in decreased affinity for CD25 while maintaining normal binding with IL-2Rβγ [22] . No- mutein inhibited, in an NK-cell dependent manner, the metastasis of the B16 melanoma-variant MB16F0 and of 3LL-D122 Lewis lung carcinoma in mice, while exerting lower toxic adverse effects compared to wild-type IL-2. The latter aspect was also confirmed by us using the F42A mutant of IL-2 that displays lower affinity to CD25, which was better tolerated in terms of pulmonary edema than wild-type IL-2 ([19] , and unpublished data).
Another research group formulated various IL-2 muteins displaying higher affinity to CD25. In vitro, these IL-2 muteins showed superior capacity to stimulate Comparing IL-2 muteins to IL-2-cx and wild-type IL-2, IL-2 muteins show similar pharmacokinetic properties as wild-type IL-2, such as a short in vivo half-life [14] , and will thus require frequent administration to maintain therapeutic levels ( 
IL-2 fusion proteins
Various IL-2-FPs (also termed IL-2 immunocytokines) have been generated in the past twenty years (reviewed in [28] ). IL-2-FPs were devised to deliver the cytokine to the tumor microenvironment thereby increasing the local dose of IL-2 to levels sufficient to stimulate tumor-specific immune cells, while keeping systemic IL-2 levels and toxic adverse effects low. To this end, IL-2 has been fused to different antibodies or antibody fragments targeting tumor-associated antigens [28] .
Selectikine is a fully humanized IL-2-FP developed for the treatment of solid tumors and B-cell non-Hodgkin lymphoma [29] [30] [31] . Selectikine comprises mAb NHS76 recognizing single or double-stranded DNA (often released from dying tumor cells) and a CD25-directed IL-2 mutein with a D20T mutation aimed at disrupting a three-amino-acid-sequence motif in IL-2, which appears to be responsible for IL-2-binding to endothelial cells, thereby causing endothelial cell damage and VLS [32] .
Compared to IL-2, Selectikine induced only mild (grade 1) hypotension and VLS suggesting improved tolerability [31] . Selectikine monotherapy stabilized disease for more than 6 weeks in 23% (9/39) and combined with low-dose cyclophosphamide in 33% (3/9) of patients with metastatic or local advanced tumors (mostly carcinomas) refractory to standard treatments [30] . Another IL-2-FP undergoing clinical testing is hu14.18-IL-2. This immunocytokine is made of wild-type human IL-2 linked to each IgG heavy chain of the hu14.18 mAb, which recognizes disialoganglioside on tumors of neuroectodermal origin, such as neuroblastoma and melanoma [35] . In a phase II clinical trial, fourteen patients received at least two treatment cycles of hu14.18-IL-2, resulting in one partial response (7.1%) [36] . Subsequently, intratumoral administration of hu14.18-IL-2, instead of iv, was tested in the murine NXS2 neuroblastoma model, leading to increased intratumoral infiltration of NK cells and CD8 + T-cells and improved antitumor effects [37] . However, intratumoral administration might limit the application of hu14.18-IL-2 to patients with solid tumors accessible for injection. Toxic adverse effects were comparable to wild-type IL-2.
Another example of the potent therapeutic effects induced by targeting IL-2 to blood vessels was shown by administration of F16-IL2 and cytarabine to a patient with disseminated extramedullary acute myeloid leukemia [39] . 
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